Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by theo12on Jan 08, 2020 12:00pm
145 Views
Post# 30530791

Reality or dreaming

Reality or dreamingThe SP is marking time at a ridiculous low with 2 approved products.  Finally, TH had an update on preliminary revenue estimates which are low, therefore maybe bringing the SP up beating those estimates in February.  And if the revenues are lower than the estimates, I think TH board should be changed.  WOW, 2 approved products and this pityful SP.
As for those on this board who preach to wait for the lauch of phase3 and Nash to see some changes,  I think they are dreaming.  The value of their dreams should a +value over a 10 to 14 $  SP value.  But as it is now,  how much of a  +value when this TH board cannot manoeuver adequately with its actual assets.
Also,  I stil think that Th should move its business to the US as it is  ''where is the business and money decision-making process ''.

But with my actual investments, I wish to be wrong.
However,  I wonder why we never hear from the 10 larger investors who own more than 50% of TH.
Bullboard Posts